Codetta Bio Announces Commercial Availability of Concerto™ System and New Customizable Cytokine and Neuroscience Panels at AGBT 2026

Codetta Bio™, a leader in multi-omic solutions that combine ultrasensitive protein quantification with simultaneous RNA and DNA analysis, today announced major product and commercialization milestones ...

Cellipont Bioservices and Soter Bio Announce Strategic Collaboration to Support Integrated U.S. Cell Therapy Manufacturing

Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced a ...
Investing

Korro Bio’s SWOT analysis: RNA editing pioneer’s stock faces pivotal year

Korro Bio, Inc. (NASDAQ:KRRO) is at the forefront of RNA editing technology, with its lead candidate KRRO-110 poised to potentially revolutionize the treatment of Alpha-1 Antitrypsin Deficiency (AATD) ...
Seeking Alpha

Korro Bio: Interesting RNA Biotech With 2nd Half 2025 Interim Data

Korro Bio, Inc. (KRRO) is a biotech that is working on advancing its RNA editing platform OPERA to treat certain types of disorders. The first RNA edited oligonucleotide drug of its kind from this ...

Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026

Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and ...
Investing

Korro Bio’s SWOT analysis: RNA editing pioneer’s stock faces pivotal phase

Korro Bio, Inc. (NASDAQ:KRRO), a biotechnology company specializing in RNA editing technology, stands at a critical juncture in its development. The firm’s innovative approach to treating genetic ...
technologynetworks

Researchers Demonstrate the Superiority of RNA Isolation Kits from Cambio

Researchers at Swansea University selected the MO BIO RNA PowerSoil® Total RNA Isolation Kit for investigations of an important group of bacteria, following comparative tests in which the kit ...